Valneva SE(NASDAQ:VALN) jumped more than 33% in morning trading.
The company’s COVID-19 vaccine elicits a robust immune response with far fewer side effects than the Oxford/AstraZeneca plc's (NASDAQ:AZN) jab, according to Phase 3 trial results.
Valneva said its latest trial included around 4,000 participants aged 18 and older across 26 trial sites.
精彩评论